A Study of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hypothesis:
25-hydroxy vitamin D levels in non-itching hemodialysis (HD) patients will be higher than those in HD patients with itching
25-hydroxy vitamin D levels will be measured in non-itching hemodialysis patients and compared to levels previously measured in a previous study of 25-hydroxy vitamin D levels of patients complaining of itching.
| Condition |
|---|
|
Vitamin D Deficiency End Stage Renal Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | A Cross-sectional Analysis of 25-hydroxy Vitamin d Levels in Non-itching Hemodialysis Patients |
- 25 hydroxy vitamin D level [ Time Frame: up to 2 weeks ] [ Designated as safety issue: No ]Pt will have blood sample taken and fill out 1) Pruritis Survey 2) Phosphorus Restriction Compliance Survey
| Enrollment: | 50 |
| Study Start Date: | September 2011 |
| Study Completion Date: | February 2012 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
25-hydroxy vitamin D levels from non-itching HD patients in this study will be compared to 25-hydroxy vitamin D levels from our ongoing study in HD patients with itching. The primary endpoints for both studies are continuous variables. Student's t test will be used to test for statistical significance. Multiple regression analysis will be used for controlling covariates and testing the interaction among covariates.
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
ESRD patients on hemodialysis
Inclusion Criteria:
- Hemodialysis treatment for > 3 months No complaints of itching within 1 month prior to study enrollment
Exclusion Criteria:
- Age < 18 years
- Failure to provide informed consent
- Intact PTH < 70 pg/ml or > 1,000 pg/ml
- Serum phosphorus > 7.0
- Serum calcium (adjusted for albumin)> 11
- Active malignancy
- Likelihood of imminent renal transplantation
- Current ergocalciferol treatment
Contacts and Locations| United States, New York | |
| Winthrop University Hospital | |
| Mineola, New York, United States, 11501 | |
| Winthrop University Hospital Dialysis Unit | |
| Mineola, New York, United States, 11023 | |
| Principal Investigator: | Mary Schanler, RD | Winthrop University Hospital |
More Information
No publications provided
| Responsible Party: | Mary Schanler, Administrative Dietitian, Winthrop University Hospital |
| ClinicalTrials.gov Identifier: | NCT01548716 History of Changes |
| Other Study ID Numbers: | 11318 |
| Study First Received: | February 24, 2012 |
| Last Updated: | March 5, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Winthrop University Hospital:
|
Pruritis in hemodialysis patients 25-Vitamin D in chronic kidney disease |
Additional relevant MeSH terms:
|
Kidney Diseases Kidney Failure, Chronic Vitamin D Deficiency Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency Avitaminosis Deficiency Diseases Malnutrition |
Nutrition Disorders Vitamin D Ergocalciferols Vitamins Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 19, 2013